Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Whether Early Steroid dose is Associated with Lower Mortality in COVID-19 Critically Ill Patients-An Exploratory Chart Review

Author(s): Abhishek Goyal*, Ankur Joshi, Saurabh Saigal, Dodda Brahmam, Yogesh Niwariya, Alkesh Khurana, Sagar Khadanga and Arun Mitra

Volume 18, Issue 1, 2023

Published on: 18 October, 2022

Page: [42 - 53] Pages: 12

DOI: 10.2174/2772434417666220817121439

Price: $65

conference banner
Abstract

Introduction: Steroids have shown its usefulness in critically ill COVID-19 patients. However, the time of starting steroid and dose tailored to severity remain a matter of inquiry due to still emerging evidences and wide-ranging concerns of benefits and harms. We did a retrospective record analysis in an apex teaching hospital ICU setting to explore optimal doses and duration of steroid therapy which can decrease mortality.

Methods: 114 adults with COVID-19-ARDS admitted to ICU between 20th March-15th August 2020 were included in chart review. We did preliminary exploratory analysis (rooted in steroid therapy matrix categorized by dose and duration) to understand the effect of several covariates on survival. This was followed by univariate and multivariate Cox proportion hazard regression analysis and model diagnostics.

Results: Exploratory analysis and visualization indicated age, optimal steroid, severity (measured in P/F) of disease and infection status as potential covariates for survival. Univariate cox regression analysis showed significant positive association of age > 60 years {2.6 (1.5-4.7)} and protective effect of optimum steroid {0.38(0.2-0.72)} on death (hazard) in critically ill patients. Multivariate cox regression analysis after adjusting effect of age showed protective effect of optimum steroid on hazard defined as death {0.46(0.23-0.87), LR = 17.04, (p = 2e-04)}. The concordance was 0.70 and model diagnostics fulfilled the assumption criteria for proportional hazard model.

Conclusion: Optimal dose steroid as per defined ‘optimum’ (<24 hours and doses tailored to P/F at presentation) criteria can offer protective effect from mortality which persists after adjusting for age. This protective effect was not found to be negatively influenced by the risk of infection.

Keywords: COVID-19, ARDS, Pulse Steroids, Mortality, methyl prednisolone, ICU, steroids

« Previous Next »
Graphical Abstract

[1]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA 2020; 323(18): 1824-36.
[http://dx.doi.org/10.1001/jama.2020.6019] [PMID: 32282022]
[2]
Goyal A, Saigal S, Niwariya Y, Sharma J, Singh P. Successful use of tPA for thrombolysis in COVID related ARDS: A case series. J Thromb Thrombolysis 2020; 51(2): 293-6.
[http://dx.doi.org/10.1007/s11239-020-02208-2] [PMID: 32617806]
[3]
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020; 53: 25-32.
[http://dx.doi.org/10.1016/j.cytogfr.2020.05.003] [PMID: 32446778]
[4]
Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: Survival and clinical outcomes. Chest 2020; 158(4): 1397-408.
[5]
Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015; 13: 55.
[http://dx.doi.org/10.1186/s12969-015-0055-3] [PMID: 26634252]
[6]
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19(6): 102537.
[http://dx.doi.org/10.1016/j.autrev.2020.102537] [PMID: 32251717]
[7]
The Recovery Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 -Preliminary Report. N Engl J Med 2021; 384: 693-04. https://www.nejm.org/doi/full/10.1056/NEJMoa2021436
[8]
The R Foundation: The R Project for Statistical Computing. Available from: https://www.r-project.org/
[9]
De Azevedo JRA. Comparison of the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID- 19. A prospective randomized controlled phase II trial. Report No.: NCT04377503, 2020 https://clinicaltrials.gov/ct2/show/NCT04377503
[10]
Sterne JA, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A meta-analysis. JAMA 2020; 324(13): 1330-41.
[11]
Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med 2020; 15(8): 489-93.
[12]
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH. New-onset diabetes in COVID-19. N Engl J Med 2020; 383(8): 789-90.
[http://dx.doi.org/10.1056/NEJMc2018688]
[13]
Wu J, Liu X, Liu J, et al. Coronavirus disease 2019 test results after clinical recovery and hospital discharge among patients in China. JAMA Netw Open 2020; 3(5): e209759-9.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.9759] [PMID: 32442288]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy